Business
DNA ImmunoBody Patent Granted in first market
DNA ImmunoBody Patent Granted in first market.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0587N Scancell Holdings Plc 03 September 2013 \n \n\n3 September 2013\nScancell Holdings Plc\n('Scancell')\n \nDNA ImmunoBody® Patent Granted in first market\n \n \nScancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody® technology has been granted in Australia. This is the first jurisdiction to approve the DNA patent and is a key landmark on the road to comprehensively protecting Scancell's DNA ImmunoBody® platform technology.\n \nThe patent, which covers the DNA ImmunoBody® platform technology and is of importance for the protection of Scancell's entire pipeline of ImmunoBody® vaccines, has also been filed in the US, Europe and other major markets. The composition of matter patent for SCIB1, Scancell's ImmunoBody® vaccine for the treatment of melanoma, has already been granted in Europe, Turkey and South Africa.\n \nScancell's protein ImmunoBody® patent has been approved in the US, Europe, Japan and Australia.\n \nDr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:\n \n\"Our lead ImmunoBody® for melanoma, SCIB1, currently in Phase I/II clinical trials is based on the DNA approach. The approval of this DNA patent is therefore a very important step in the development and commercialisation of our ImmunoBody® platform. Scancell continues to build its growing portfolio of intellectual property in parallel with advancing the clinical trial programme on SCIB1.\"\n \n \n-ENDS-\n \n \nFor Further Information: \n \n\n\n\n\nDr Richard Goodfellow, Joint CEO\nProfessor Lindy Durrant, Joint CEO \n\n\nScancell Holdings Plc\nScancell Holdings Plc\n\n\n+ 44 (0) 74 2323 0497 \n+ 44 (0) 74 2323 0497 \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCamilla Hume/Stephen Keys\n\n\nCenkos\n\n\n+ 44 (0) 20 7397 8900\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSimon Conway/Mo Noonan\n\n\nFTI Consulting\n\n\n+ 44 (0) 20 7831 3113\n\n\n\n\n \n \nAbout Scancell\n \nScancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Prelim...